

Resolution on notice of Annual General Meeting of Vitrolife AB (publ)

The Board of Directors has resolved that the Annual General Meeting of Vitrolife AB (publ) will take place on Wednesday 27 April 2022 at 4.00 pm.

The Notice will be published no later than 30 March 2022.

Gothenburg, 22 March 2022
VITROLIFE AB (publ)
The Board of Directors

Contact:

Jón Sigurdsson, Chairman of the Board, email: jsigurdsson@ossur.com
Patrik Tolf, CFO, phone +46 (0)31 766 90 21, email: ptolf@vitrolife.com

Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife is supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,200 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aims to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

The information was submitted for publication, through the agency of the contact persons set out above, at 2:15 pm CET on March 22, 2022.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.